AR084235A1 - Composiciones farmaceuticas que comprenden alisporivir - Google Patents
Composiciones farmaceuticas que comprenden alisporivirInfo
- Publication number
- AR084235A1 AR084235A1 ARP110104622A ARP110104622A AR084235A1 AR 084235 A1 AR084235 A1 AR 084235A1 AR P110104622 A ARP110104622 A AR P110104622A AR P110104622 A ARP110104622 A AR P110104622A AR 084235 A1 AR084235 A1 AR 084235A1
- Authority
- AR
- Argentina
- Prior art keywords
- percent
- composition
- glycerides
- weight
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 title abstract 2
- 229950004789 alisporivir Drugs 0.000 title abstract 2
- 108010058359 alisporivir Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229960003511 macrogol Drugs 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 abstract 1
- FUWVMBCPMRAWPG-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-hydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)OCC(O)CO FUWVMBCPMRAWPG-UHFFFAOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005642 Oleic acid Substances 0.000 abstract 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 239000002285 corn oil Substances 0.000 abstract 1
- 235000005687 corn oil Nutrition 0.000 abstract 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 229940087068 glyceryl caprylate Drugs 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- 229940057917 medium chain triglycerides Drugs 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 abstract 1
- 239000001593 sorbitan monooleate Substances 0.000 abstract 1
- 229940035049 sorbitan monooleate Drugs 0.000 abstract 1
- 235000011069 sorbitan monooleate Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 239000001069 triethyl citrate Substances 0.000 abstract 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000013769 triethyl citrate Nutrition 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica para su administración oral, la cual comprende alisporivir en una cantidad de aproximadamente el 15 por ciento a aproximadamente el 20 por ciento en peso de la composición, y agua en una cantidad de aproximadamente el 2 por ciento a aproximadamente el 15 por ciento en peso de la composición.Reivindicación 10: Una composición farmacéutica para su administración oral, la cual comprende: 1) alisporivir, en una cantidad de aproximadamente el 5 por ciento a aproximadamente el 15 por ciento en peso de la composición; 2) un componente lipofílico seleccionado a partir del grupo que consiste en triglicéridos de cadena mediana, mono-, di-, tri-glicéridos de aceite de maíz, mono-oleato de sorbitán, glicéridos de linoleoílo Macrogol, y ácido oleico; 3) un tensoactivo seleccionado a partir del grupo que consiste en hidroxiestearato de glicerol Macrogol, glicéridos de caprilocaproílo Macrogol-8, succinato de polietilenglicol Vitamina E, y caprilato de glicerilo; 4) un componente hidrofílico seleccionado a partir del grupo que consiste en etanol, polietilenglicol, citrato de trietilo, mono-etil-éter de dietilenglicol, y propilenglicol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42249910P | 2010-12-13 | 2010-12-13 | |
| IB2011000319 | 2011-02-18 | ||
| IB2011000653 | 2011-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084235A1 true AR084235A1 (es) | 2013-05-02 |
Family
ID=45346477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104622A AR084235A1 (es) | 2010-12-13 | 2011-12-12 | Composiciones farmaceuticas que comprenden alisporivir |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20140005123A1 (es) |
| EP (1) | EP2651396B1 (es) |
| JP (2) | JP6259288B2 (es) |
| KR (1) | KR101928589B1 (es) |
| CN (2) | CN103282022A (es) |
| AR (1) | AR084235A1 (es) |
| AU (3) | AU2011344331A1 (es) |
| BR (1) | BR112013014606A2 (es) |
| CA (1) | CA2819167C (es) |
| CL (1) | CL2013001684A1 (es) |
| CO (1) | CO6761388A2 (es) |
| CY (1) | CY1119468T1 (es) |
| DK (1) | DK2651396T3 (es) |
| EC (1) | ECSP13012679A (es) |
| ES (1) | ES2643135T3 (es) |
| HR (1) | HRP20171485T1 (es) |
| HU (1) | HUE036784T2 (es) |
| IL (1) | IL226554A (es) |
| JO (1) | JO3337B1 (es) |
| LT (1) | LT2651396T (es) |
| MA (1) | MA34709B1 (es) |
| MX (1) | MX351667B (es) |
| MY (1) | MY165088A (es) |
| NZ (1) | NZ610950A (es) |
| PE (1) | PE20140104A1 (es) |
| PL (1) | PL2651396T3 (es) |
| PT (1) | PT2651396T (es) |
| RU (1) | RU2639482C2 (es) |
| SG (2) | SG10201509833YA (es) |
| SI (1) | SI2651396T1 (es) |
| TW (1) | TWI599368B (es) |
| WO (1) | WO2012080176A2 (es) |
| ZA (1) | ZA201303721B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012082689A1 (en) | 2010-12-13 | 2012-06-21 | Array Biopharma Inc. | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| WO2015008223A1 (en) | 2013-07-17 | 2015-01-22 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir and ribavirin |
| WO2015136455A1 (en) | 2014-03-13 | 2015-09-17 | Novartis Ag | New treatments of hepatitis c virus infection |
| AR114930A1 (es) * | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1274354A (fr) | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| FR2697040B1 (fr) | 1992-10-21 | 1994-12-30 | Ind Entreprise | Elément de protection contre le bruit et son utilisation. |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| SE504582C2 (sv) | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyklosporinkomposition baserad på en L2-fas |
| ID25908A (id) | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| WO1999056727A2 (en) * | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| EP1091975B1 (fr) * | 1998-07-01 | 2005-12-14 | Debiopharm S.A. | Nouvelle cyclosporine ayant un profil d'activite ameliore |
| GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| GB0001928D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| US6979672B2 (en) | 2002-12-20 | 2005-12-27 | Polichem, S.A. | Cyclosporin-based pharmaceutical compositions |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| SG139750A1 (en) * | 2004-10-01 | 2008-02-29 | Debiopharm Sa Ch | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin |
| NZ555143A (en) | 2004-12-23 | 2009-12-24 | Novartis Ag | Compositions for HCV treatment |
| GB0504950D0 (en) | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
| BRPI0920502A2 (pt) | 2008-11-06 | 2015-12-22 | Debio Rech Pharma Sa | compostos cicloundecadepsipeptídeos e seu uso como medicamento |
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
-
2011
- 2011-12-11 JO JOP/2011/0373A patent/JO3337B1/ar active
- 2011-12-12 MY MYPI2013001865A patent/MY165088A/en unknown
- 2011-12-12 NZ NZ610950A patent/NZ610950A/en not_active IP Right Cessation
- 2011-12-12 HU HUE11794739A patent/HUE036784T2/hu unknown
- 2011-12-12 CN CN2011800598202A patent/CN103282022A/zh active Pending
- 2011-12-12 US US13/992,948 patent/US20140005123A1/en not_active Abandoned
- 2011-12-12 PT PT117947390T patent/PT2651396T/pt unknown
- 2011-12-12 WO PCT/EP2011/072463 patent/WO2012080176A2/en active Application Filing
- 2011-12-12 AU AU2011344331A patent/AU2011344331A1/en not_active Abandoned
- 2011-12-12 CA CA2819167A patent/CA2819167C/en not_active Expired - Fee Related
- 2011-12-12 LT LTEP11794739.0T patent/LT2651396T/lt unknown
- 2011-12-12 BR BR112013014606A patent/BR112013014606A2/pt not_active Application Discontinuation
- 2011-12-12 AR ARP110104622A patent/AR084235A1/es unknown
- 2011-12-12 PE PE2013001400A patent/PE20140104A1/es active IP Right Grant
- 2011-12-12 CN CN201510548088.5A patent/CN105125489B/zh not_active Expired - Fee Related
- 2011-12-12 JP JP2013543687A patent/JP6259288B2/ja not_active Expired - Fee Related
- 2011-12-12 KR KR1020137018234A patent/KR101928589B1/ko active IP Right Grant
- 2011-12-12 ES ES11794739.0T patent/ES2643135T3/es active Active
- 2011-12-12 PL PL11794739T patent/PL2651396T3/pl unknown
- 2011-12-12 SG SG10201509833YA patent/SG10201509833YA/en unknown
- 2011-12-12 RU RU2013132543A patent/RU2639482C2/ru not_active IP Right Cessation
- 2011-12-12 DK DK11794739.0T patent/DK2651396T3/en active
- 2011-12-12 SG SG2013040712A patent/SG190894A1/en unknown
- 2011-12-12 SI SI201131314T patent/SI2651396T1/sl unknown
- 2011-12-12 EP EP11794739.0A patent/EP2651396B1/en active Active
- 2011-12-12 TW TW100145812A patent/TWI599368B/zh not_active IP Right Cessation
- 2011-12-12 MX MX2013006525A patent/MX351667B/es active IP Right Grant
-
2013
- 2013-05-22 ZA ZA2013/03721A patent/ZA201303721B/en unknown
- 2013-05-23 IL IL226554A patent/IL226554A/en active IP Right Grant
- 2013-06-05 MA MA35960A patent/MA34709B1/fr unknown
- 2013-06-12 CL CL2013001684A patent/CL2013001684A1/es unknown
- 2013-06-13 EC ECSP13012679 patent/ECSP13012679A/es unknown
- 2013-06-14 CO CO13142692A patent/CO6761388A2/es unknown
-
2016
- 2016-02-19 AU AU2016201053A patent/AU2016201053B2/en not_active Ceased
- 2016-05-12 US US15/153,035 patent/US10188696B2/en not_active Expired - Fee Related
-
2017
- 2017-08-24 JP JP2017161652A patent/JP2018027949A/ja active Pending
- 2017-10-04 HR HRP20171485TT patent/HRP20171485T1/hr unknown
- 2017-10-09 AU AU2017245296A patent/AU2017245296A1/en not_active Abandoned
- 2017-10-12 CY CY20171101068T patent/CY1119468T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7250865B2 (ja) | 固溶体組成物および心血管疾患における使用 | |
| NZ596657A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
| ES2531599T3 (es) | Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales | |
| WO2010117873A3 (en) | Progesterone solutions for increased bioavailability | |
| JP2014509655A5 (es) | ||
| AR084235A1 (es) | Composiciones farmaceuticas que comprenden alisporivir | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| EA201290982A1 (ru) | Фармацевтические композиции, препятствующие злоупотреблению | |
| ES2616022T3 (es) | Composiciones farmacéuticas de curcumina | |
| BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| NI201200038A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
| BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
| CA2864118A1 (en) | Formulations of bendamustine | |
| JP2015520235A5 (es) | ||
| NZ581589A (en) | Solubilized sterile injectable formulation of docetaxel without Tween 80 | |
| JP2012524771A5 (es) | ||
| CO6210803A2 (es) | Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel | |
| CO6400183A2 (es) | Formas de dosificación oral de bendamustina | |
| MX354647B (es) | Composicion farmaceutica anticonvulsiva transnasal que comprende un anticonvulsivante escasamente soluble. | |
| RU2017129161A (ru) | Композиции липидов | |
| CR20120623A (es) | Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona | |
| DOP2011000382A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas | |
| RU2013126259A (ru) | Фармацевтическая композиция таксоидов | |
| FR2915683B1 (fr) | Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |